BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 22419518)

  • 1. Enhancement of natural killer cell effector functions against selected lymphoma and leukemia cell lines by dasatinib.
    Hassold N; Seystahl K; Kempf K; Urlaub D; Zekl M; Einsele H; Watzl C; Wischhusen J; Seggewiss-Bernhardt R
    Int J Cancer; 2012 Sep; 131(6):E916-27. PubMed ID: 22419518
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modulation of natural killer cell effector functions through lenalidomide/dasatinib and their combined effects against multiple myeloma cells.
    Jungkunz-Stier I; Zekl M; Stühmer T; Einsele H; Seggewiss-Bernhardt R
    Leuk Lymphoma; 2014 Jan; 55(1):168-76. PubMed ID: 23573828
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The BCR/ABL-inhibitors imatinib, nilotinib and dasatinib differentially affect NK cell reactivity.
    Salih J; Hilpert J; Placke T; Grünebach F; Steinle A; Salih HR; Krusch M
    Int J Cancer; 2010 Nov; 127(9):2119-28. PubMed ID: 20143399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combining dasatinib with dexamethasone long-term leads to maintenance of antiviral and antileukemia specific cytotoxic T cell responses in vitro.
    Nerreter T; Distler E; Köchel C; Einsele H; Herr W; Seggewiss-Bernhardt R
    Exp Hematol; 2013 Jul; 41(7):604-614.e4. PubMed ID: 23466625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Direct effect of dasatinib on proliferation and cytotoxicity of natural killer cells in in vitro study.
    Uchiyama T; Sato N; Narita M; Yamahira A; Iwabuchi M; Furukawa T; Sone H; Takahashi M
    Hematol Oncol; 2013 Sep; 31(3):156-63. PubMed ID: 23108877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dasatinib inhibits recombinant viral antigen-specific murine CD4+ and CD8+ T-cell responses and NK-cell cytolytic activity in vitro and in vivo.
    Fraser CK; Blake SJ; Diener KR; Lyons AB; Brown MP; Hughes TP; Hayball JD
    Exp Hematol; 2009 Feb; 37(2):256-65. PubMed ID: 19056158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy.
    Mustjoki S; Ekblom M; Arstila TP; Dybedal I; Epling-Burnette PK; Guilhot F; Hjorth-Hansen H; Höglund M; Kovanen P; Laurinolli T; Liesveld J; Paquette R; Pinilla-Ibarz J; Rauhala A; Shah N; Simonsson B; Sinisalo M; Steegmann JL; Stenke L; Porkka K
    Leukemia; 2009 Aug; 23(8):1398-405. PubMed ID: 19295545
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Profound inhibition of antigen-specific T-cell effector functions by dasatinib.
    Weichsel R; Dix C; Wooldridge L; Clement M; Fenton-May A; Sewell AK; Zezula J; Greiner E; Gostick E; Price DA; Einsele H; Seggewiss R
    Clin Cancer Res; 2008 Apr; 14(8):2484-91. PubMed ID: 18413841
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dasatinib suppresses in vitro natural killer cell cytotoxicity.
    Blake SJ; Bruce Lyons A; Fraser CK; Hayball JD; Hughes TP
    Blood; 2008 Apr; 111(8):4415-6. PubMed ID: 18398058
    [No Abstract]   [Full Text] [Related]  

  • 10. In vitro increased natural killer cell activity of metastatic melanoma patients with interferon-α alone as opposed to its combination with 13-cis retinoic acid is associated with modulation of NKG2D and CD161 activating receptor expression.
    Konjevic G; Mirjacic-Martinovic K; Vuletic A; Babovic N
    J BUON; 2012; 17(4):761-9. PubMed ID: 23335538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibitors of SRC kinases impair antitumor activity of anti-CD20 monoclonal antibodies.
    Winiarska M; Bojarczuk K; Pyrzynska B; Bil J; Siernicka M; Dwojak M; Bobrowicz M; Miazek N; Zapala P; Zagozdzon A; Krol M; Syta A; Podszywalow-Bartnicka P; Pilch Z; Dabrowska-Iwanicka A; Juszczynski P; Efremov DG; Slabicki M; Zenz T; Le Roy A; Olive D; Rygiel TP; Leusen JH; Golab J
    MAbs; 2014; 6(5):1300-13. PubMed ID: 25517315
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells.
    Fiskus W; Pranpat M; Balasis M; Bali P; Estrella V; Kumaraswamy S; Rao R; Rocha K; Herger B; Lee F; Richon V; Bhalla K
    Clin Cancer Res; 2006 Oct; 12(19):5869-78. PubMed ID: 17020995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An Fc-optimized NKG2D-immunoglobulin G fusion protein for induction of natural killer cell reactivity against leukemia.
    Steinbacher J; Baltz-Ghahremanpour K; Schmiedel BJ; Steinle A; Jung G; Kübler A; André MC; Grosse-Hovest L; Salih HR
    Int J Cancer; 2015 Mar; 136(5):1073-84. PubMed ID: 25046567
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity.
    Pende D; Rivera P; Marcenaro S; Chang CC; Biassoni R; Conte R; Kubin M; Cosman D; Ferrone S; Moretta L; Moretta A
    Cancer Res; 2002 Nov; 62(21):6178-86. PubMed ID: 12414645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Upregulation of NKG2D ligands in acute lymphoblastic leukemia and non-Hodgkin lymphoma cells by romidepsin and enhanced in vitro and in vivo natural killer cell cytotoxicity.
    Satwani P; Bavishi S; Saha A; Zhao F; Ayello J; van de Ven C; Chu Y; Cairo MS
    Cytotherapy; 2014 Oct; 16(10):1431-40. PubMed ID: 24856896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of cell growth and up-regulation of MAD2 in human oesophageal squamous cell carcinoma after treatment with the Src/Abl inhibitor dasatinib.
    Wang L; Guo B; Wang R; Jiang Y; Qin S; Liang S; Zhao Y; Guo W; Li K; Fan X
    Clin Sci (Lond); 2012 Jan; 122(1):13-24. PubMed ID: 21751967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dasatinib enhances migration of monocyte-derived dendritic cells by reducing phosphorylation of inhibitory immune receptors Siglec-9 and Siglec-3.
    Nerreter T; Köchel C; Jesper D; Eichelbrönner I; Putz E; Einsele H; Seggewiss-Bernhardt R
    Exp Hematol; 2014 Sep; 42(9):773-82.e1-3. PubMed ID: 24882272
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sorafenib paradoxically activates the RAS/RAF/ERK pathway in polyclonal human NK cells during expansion and thereby enhances effector functions in a dose- and time-dependent manner.
    Lohmeyer J; Nerreter T; Dotterweich J; Einsele H; Seggewiss-Bernhardt R
    Clin Exp Immunol; 2018 Jul; 193(1):64-72. PubMed ID: 29573266
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Src/ABL kinase inhibitor dasatinib (BMS-354825) inhibits function of normal human T-lymphocytes in vitro.
    Blake S; Hughes TP; Mayrhofer G; Lyons AB
    Clin Immunol; 2008 Jun; 127(3):330-9. PubMed ID: 18395492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Upregulation of NKG2D ligands and enhanced natural killer cell cytotoxicity by hydralazine and valproate.
    Chávez-Blanco A; De la Cruz-Hernández E; Domínguez GI; Rodríguez-Cortez O; Alatorre B; Pérez-Cárdenas E; Chacón-Salinas R; Trejo-Becerril C; Taja-Chayeb L; Trujillo JE; Contreras-Paredes A; Dueñas-González A
    Int J Oncol; 2011 Dec; 39(6):1491-9. PubMed ID: 21805029
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.